Research programme: peroxisome proliferator activated receptor agonists - Albireo Pharma
Latest Information Update: 12 Jan 2017
At a glance
- Originator Albireo AB
- Developer Albireo Pharma
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 18 Dec 2014 Preclinical trials in Inflammatory bowel disease in Sweden (unspecified route)